References
- Naban, Kamat, and Kish. Leukemia and Lymphoma this issue
- Social Security Administration. Retirement and Survivors Benefits: Life Expectancy Calculator. Available from: https://www.ssa.gov/oact/population/longevity.html
- DiNardo C, Pollyea D, Jonas B, et al. Updated safety and efficacy of venetoclax and decitabine or azacytidine in treatment-naïve elderly patients with acute myeloid leukemia. Blood. 2017;130:2628–2629.
- Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukaemia?. Leukemia. 2017;31:1255–1258.
- Estey E, Gale RP, Sekeres M. New drugs in AML: uses and abuses. Leukemia. 2018;32:1479–1481.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574518.html
- Walter R, Kantarjian H, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Jco. 2010;28:1766–1771.
- Othus M, Sekeres M, Nand S, et al. Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia. 2018. doi: 10.1038/s41375-018-0275-x. [Epub ahead of print].
- Kayastha N, Wolf S, Locke S, et al. The impact of remission status on patients’ experiences with acute myeloid leukemia: an exploratory analysis of longitudinal patient-reported outcome data. Support Care Cancer. 2018; 26:1437–1445.